XCancer

A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours

Description:

The purpose of the study is to evaluate the safety and biodistribution of \[I-124\]-CPD-1028 Injection in cancer patients with solid tumours.

Sponsor:

Unknown Organization

Phase:

Phase 1

Contacts:

Eric Burak, PhD (STUDY_DIRECTOR)

Government Study Link:

NCT02134340 - Click here to see study on

ClinicalTrials.gov

CPD-1028

Isotope(s):
Target(s):
  • IGF-1R
Inclusion
  • Patients must have adequate organ and marrow function, vital signs and ECG.
  • Patients must have progressed after at least first-line chemotherapy and have an Eastern Cooperative Oncology Group (ECOG) status of 0, 1 or 2.
  • All patients must have archival tumour samples available and must have verification of IGF-1R expression.
  • Females of childbearing potential must not be pregnant and both males and females must use adequate forms of contraception.
  • 1. Age ≥18 years old with life expectancy \> 12 weeks with confirmed metastatic or unresectable malignancy
Exclusion
  • Patients who are currently taking antithyroid medications and lithium or potassium sparing diuretics.
  • 1. Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from previous treatment.
  • Patients who have received a therapeutic radiopharmaceutical in the past year or who are currently receiving any other investigational agents.
  • Subjects with known or suspected allergies or contraindications to the investigational agents and iodine
  • Previous treatment with IGF-1R inhibitors.